Novartis Phase Iii Psmafore Study Of Pluvicto A Psma Targeted Radioligand Therapy Meets Primary Endpoint
Novartis Announced The Pivotal Phase Iii Psmafore Study With Pluvicto (Inn: Lutetium (177Lu) Vipivotide Tetraxetan), A Prostate-Specific Membrane Antigen (Psma)-Targeted Radioligand Therapy, Met Its Primary Endpoint.Pluvicto Demonstrated A Statistically Significant And Clinically Meaningful Improvement In Radiographic Progression-Free Survival (Rpfs) In Patients With Psma
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!